Similarly, mTOR inhibitors like everolimus have been investigated for used as an adjuvant therapy in advanced HNSCC with promising therapeutic outcomes (Nathan et al., 2022; Massarelli et al., 2015). This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.